Drugs / Cecolin 9
Cecolin 9
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT04782895 | Mar 2021 → May 2022 | anogenital human papillomavirus infection, cervical cancer | Xiamen University | Completed | No outcome recorded |
| Phase 3 | NCT04537156 | Sep 2020 → Dec 2027 expected | anogenital human papillomavirus infection, cervical cancer, cervical intraepithelial neoplasia | Xiamen University | Active not recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07668271 | May 2026 → Feb 2027 expected | human papilloma virus infection | Xiamen Innovax Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cecolin 9 | “This study aimed to compare the immunogenicity of the E coli-produced HPV 9-valent vaccine Cecolin 9 (against HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) with Gardasil 9.” PMID 37475116 ↗ Jul 20232“We aimed to report the efficacy, safety, and immunogenicity profile of the nine-valent (9vHPV) vaccine, Cecolin 9.” PMID 42379209 ↗ Jun 2026 |
| Known as | 9-valent HPV vaccine | “9-valent HPV vaccine (Cecolin 9)” NCT07668271 ↗ |
| Known as | 9vHPV vaccine | “BACKGROUND: Cecolin, a bivalent human papillomavirus (2vHPV) vaccine produced with Escherichia coli, has demonstrated safety and efficacy and is now widely used globally. We...” PMID 42379209 ↗ Jun 2026 |
| Modality | Vaccine | “E coli-produced HPV 9-valent vaccine Cecolin 9” PMID 37475116 ↗ Jul 2023 |
| Route | Intramuscular | “Three doses administered intramuscularly at 0, 45 day and 6 month.” NCT04782895 ↗ |